• Nicholas W Lange, David M Salerno, Chelsea M Sammons, Arun B Jesudian, Elizabeth C Verna, and Robert S Brown.
• Department of Pharmacy, NewYork-Presbyterian Hospital, New York, New York.
• Clin Transplant. 2018 Dec 1; 32 (12): e13415.

BackgroundTo investigate the impact of delayed calcineurin inhibitor (CNI) initiation in liver transplant recipients (LTR) with peri-operative renal insufficiency receiving basiliximab induction, we compared renal outcomes of LTR stratified by the degree of achieved post-operative renal recovery (RR) prior to CNI initiation.MethodsAll adult LTR transplanted between 01/2007 and 12/2015 who received basiliximab were included. Patients who received multi-organ transplantations, were repeat transplant recipients, or expired prior to post-operative day (POD) 90 were excluded. The primary outcome of our retrospective analysis was renal function at POD 90.ResultsA total of 210 patients were included in our final analysis. Most patients were Caucasian males undergoing liver transplantation for liver disease secondary to hepatitis C virus. Baseline characteristics were similar among the evaluable population. Estimated GFR was significantly higher among patients with the greatest degree of post-operative renal recovery at POD 90; however, this difference did not persist at POD 180. There was no significant difference in incidence or severity of biopsy-proven acute rejection (BPAR) at any measured time point.ConclusionsDelayed CNI initiation following liver transplantation in patients with post-operative renal insufficiency who receive basiliximab induction does not adversely affect the incidence of BPAR or long-term renal outcomes.© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

33 keywords...

hide…